# GlucoFend (Cinnamomum burmannii Extract)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/glucofend
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-05
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Cinnamomum burmannii Extract, Indonesian Cinnamon Extract, Cassia Cinnamon Extract, Cinnamomum burmannii, C. burmannii Extract, Padang Cassia Extract, Korintje Cinnamon Extract

## Overview

GlucoFend is a proprietary extract of Cinnamomum burmannii, a cinnamon species containing cinnamaldehyde and A-type proanthocyanidins as its primary bioactive compounds. These constituents are theorized to influence insulin signaling pathways, though no clinical trials have been conducted on the GlucoFend branded extract specifically.

## Health Benefits

• No specific health benefits for GlucoFend were identified in peer-reviewed literature
• The research dossier yielded no clinical trials or studies on this branded ingredient
• General cinnamon research (not GlucoFend-specific) suggests mixed effects on fasting glucose in small trials
• No evidence quality can be assigned due to absence of GlucoFend-specific studies
• Manufacturer claims for glucose management remain unverified in the scientific literature

## Mechanism of Action

Cinnamaldehyde, the predominant phenylpropanoid in Cinnamomum burmannii, is proposed to activate insulin receptor substrate-1 (IRS-1) phosphorylation and enhance GLUT4 transporter translocation to cell membranes, improving peripheral glucose uptake. A-type proanthocyanidins may inhibit intestinal alpha-glucosidase and alpha-amylase enzymes, slowing postprandial glucose absorption. Additionally, cinnamaldehyde has shown in vitro inhibition of protein tyrosine phosphatase 1B (PTP1B), an enzyme that negatively regulates insulin receptor signaling, though these mechanisms have not been confirmed for the GlucoFend extract specifically.

## Clinical Summary

No peer-reviewed clinical trials have been published on the GlucoFend branded extract of Cinnamomum burmannii. General research on Cinnamomum burmannii and related cinnamon species includes small randomized controlled trials, typically involving 30 to 90 participants over 8 to 12 weeks, showing modest and inconsistent reductions in fasting [blood glucose](/ingredients/condition/weight-management) ranging from 3% to 10% in some prediabetic cohorts. A 2013 meta-analysis of cinnamon species broadly found statistically significant but clinically modest fasting glucose reductions of approximately 8.2 mg/dL on average, with high heterogeneity across studies. The overall evidence base is considered preliminary, and results cannot be extrapolated directly to GlucoFend without extract-specific data.

## Nutritional Profile

GlucoFend is a proprietary extract of Cinnamomum burmannii (Korintje/Indonesian cinnamon) bark, standardized for specific bioactive compounds rather than consumed as a whole food ingredient. As an extract, macronutrient content (fat, protein, carbohydrate) is negligible at typical supplemental doses (commonly 100–500 mg/day). Key bioactive compounds inherent to Cinnamomum burmannii bark include: (1) Cinnamaldehyde (trans-cinnamaldehyde): the principal volatile phenylpropanoid, typically comprising 55–90% of bark essential oil fraction; associated with insulin-mimetic activity in preclinical models. (2) Type-A Procyanidins (condensed tannins): polymeric polyphenols, particularly doubly-linked A-type linkages, reported at approximately 1–3% of dry bark weight in Cinnamomum species; these are the compounds most associated with glucose transporter (GLUT4) upregulation in cell studies. (3) Coumarin: present at notably higher concentrations in Cinnamomum burmannii compared to Ceylon cinnamon (C. verum), ranging from 1,000–12,000 mg/kg dry weight (vs. <10 mg/kg in C. verum); this represents a meaningful safety distinction, as the European Food Safety Authority (EFSA) tolerable daily intake is 0.1 mg/kg body weight. (4) Cinnamic acid and hydroxycinnamic acid derivatives: present at trace levels contributing [antioxidant activity](/ingredients/condition/antioxidant). (5) Eugenol: minor volatile phenol component, typically <5% of volatile fraction. (6) Minerals from whole bark: trace manganese (~1.5 mg/g dry bark), calcium, and iron, though extraction processes may reduce mineral content significantly. Bioavailability notes: cinnamaldehyde undergoes rapid first-pass [metabolism](/ingredients/condition/weight-management) to cinnamic acid; procyanidin bioavailability is limited by molecular size and [gut microbiome](/ingredients/condition/gut-health)-dependent breakdown; coumarin is well-absorbed orally and hepatotoxic at elevated exposures. No GlucoFend-specific standardization certificate or certificate of analysis has been identified in the public domain, so precise compound concentrations for this branded extract specifically remain undisclosed by the manufacturer.

## Dosage & Preparation

No clinically studied dosages, forms, or standardization levels for GlucoFend were identified in the research. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Cinnamomum burmannii contains notably high levels of coumarin, a compound associated with hepatotoxicity at elevated intakes, distinguishing it from the lower-coumarin Ceylon cinnamon (Cinnamomum verum). Individuals taking insulin, metformin, or other hypoglycemic agents should exercise caution due to potential additive glucose-lowering effects that may cause hypoglycemia. Cinnamomum burmannii extracts are generally contraindicated during pregnancy at supplemental doses due to insufficient safety data and historical use as a uterine stimulant. Those with liver conditions or taking warfarin should consult a healthcare provider, as coumarin content may interact with anticoagulant [metabolism](/ingredients/condition/weight-management) via CYP2A6 pathways.

## Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses specific to GlucoFend were found in the research. The search results focused on pharmaceutical glucose-lowering agents (PEG-loxenatide, lobeglitazone) with no mention of this cinnamon extract or relevant PMIDs.

## Historical & Cultural Context

No historical context specific to GlucoFend was found in the research. While C. burmannii has been used in Indonesian traditional medicine (Jamu) for [digestion](/ingredients/condition/gut-health) and [metabolism](/ingredients/condition/weight-management), no details were provided in the search results.

## Synergistic Combinations

No synergistic ingredients identified due to lack of GlucoFend-specific research

## Frequently Asked Questions

### What is GlucoFend and how is it different from regular cinnamon?

GlucoFend is a proprietary standardized extract derived from Cinnamomum burmannii, a cinnamon species native to Indonesia. Unlike raw cinnamon powder, a branded extract implies a specific concentration of bioactive compounds such as cinnamaldehyde or proanthocyanidins, though the exact standardization specifications for GlucoFend have not been disclosed in publicly available peer-reviewed literature.

### Has GlucoFend been clinically tested for blood sugar control?

As of the available published literature, no independent clinical trials have been conducted specifically on the GlucoFend extract. Supporting evidence relies on studies of unbranded Cinnamomum burmannii or general cinnamon species, which show mixed results with modest fasting glucose reductions in small trials. Consumers should treat any efficacy claims as extrapolated rather than directly proven.

### What is the recommended dosage of GlucoFend?

No clinically validated dosage has been established for GlucoFend specifically due to the absence of published trials on this branded ingredient. General cinnamon research has tested doses ranging from 500 mg to 3,000 mg of cinnamon powder or extract daily, but these figures cannot be directly applied to GlucoFend without knowing its standardization and concentration. Always follow manufacturer labeling and consult a healthcare provider before use.

### Is GlucoFend safe to take with metformin or diabetes medications?

Cinnamomum burmannii extracts may produce additive hypoglycemic effects when combined with medications like metformin, sulfonylureas, or insulin, potentially increasing the risk of low blood sugar episodes. While no drug interaction studies exist for GlucoFend specifically, the proposed mechanism of enhancing insulin receptor signaling and inhibiting alpha-glucosidase suggests a pharmacodynamic overlap with common antidiabetic drugs. Patients managing diabetes with prescription medications should consult their physician before adding GlucoFend.

### Does GlucoFend contain coumarin, and is that a liver concern?

Cinnamomum burmannii is one of the cinnamon species with the highest naturally occurring coumarin content, sometimes exceeding 2,000 mg per kg of dry material, compared to trace amounts in Ceylon cinnamon. Coumarin is metabolized via CYP2A6 and at high doses has been associated with hepatotoxic effects in sensitive individuals, leading the European Food Safety Authority to set a tolerable daily intake of 0.1 mg coumarin per kg of body weight. Whether GlucoFend's extraction process removes or concentrates coumarin is not publicly documented, making this a meaningful safety consideration.

### Is there published research specifically on GlucoFend as a branded ingredient?

No clinical trials or peer-reviewed studies specifically on GlucoFend (Cinnamomum burmannii extract) have been identified in the scientific literature. While general cinnamon research shows mixed results for blood sugar effects in small trials, these studies do not evaluate GlucoFend's formulation, concentration, or efficacy. Manufacturer claims for this branded ingredient lack independent clinical validation.

### Who should consider GlucoFend supplementation, and who should avoid it?

GlucoFend may be considered by individuals interested in traditional cinnamon use for general wellness, though evidence specific to this branded extract is lacking. People with liver disease, those taking blood thinners, pregnant or nursing women, and individuals with cinnamon allergies should avoid GlucoFend due to coumarin content and potential interaction risks. Anyone with diabetes should consult their healthcare provider before adding GlucoFend, as it is not a replacement for prescribed medications.

### How does GlucoFend's form affect how your body uses it?

GlucoFend is a standardized Cinnamomum burmannii extract, which may offer more consistent potency than whole cinnamon powder, though specific bioavailability data for this branded form is not available. The extraction process concentrates certain compounds, but absorption rates depend on individual digestive factors and whether it is taken with food. No research has compared GlucoFend's bioavailability to other cinnamon extract forms or whole cinnamon.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*